Hematologic Neoplasms ; diagnosis ; therapy ; Humans

Most of chemical drafts that treatment malignant disease at blood- forming organs have side effects as: reduce aleukemia, glomerule, blood pigment, increase ure, creatinin or nauseate, voltmit, lose hair. However, rate and level are different in each of drafts. The other drafts, that made side effects are Doxorubicin + Ara.C (P3), MOPP (P2), CHOP (P1) and VAD (P4). Ara.C + Depersolon (P7), Hydrea + Ara.C (P6) drafts and especially is only use single Hydrea dafts that has little side-effect
Hematologic Neoplasms ; drug therapy ; Pharmaceutical Preparations

HMGB1 is a widely existing DNA-binding nuclear protein, participating in gene transcription, damage repair, recombination and stabilizing nucleosome construction. Under injury, infection and chemotherapy, HMGB1 can be released by nature immunocyte and necrosis cells as a DAMP, exerting pleiotropic biological effects by binding to RAGE, TLR and CXCL12, which lead to activation of CDC42, mitogen-activated protein kinases (MAPKs), c-IAP and NF-κB, thereby promoting angiogenesis, unlimited replicative potential, tissue invasion and metastasis. And it also involves in immune response by regulating immunocyte function as a immunocyte warning signal. Scholars have detected that HMGB1 is over expressed and released following chemotherapy and radiation therapy in cells of hematological malignancies, promoting malignant cell replication, decreasing therapeutic effect. Recently, endogenous HMGB1 has been implied to be an intrinsic modulator of autophagy and referenced to resistant to apoptosis in malignant hematosis cells. In contrast, through suppression of HMGB1 expression, tumor cell apoptosis and chemotherapeutic drug sensitivity were increased, which will be a new strategy for the treatment of hematological malignancies. In this article, the basic characteristics of HMGB1, including structure and biological features, and HMGB1 and tumors such as lymphoma, myeloproliferative neoplasms and acute myeloid leukemia are reviewed.
Animals ; HMGB1 Protein ; Hematologic Neoplasms ; therapy ; Humans

OBJECTIVETo explore the effect of structural family therapy (SFT), which refers to the application of the theory and technology of SFT for improving the internal family environment of pediatric patients through reorganization of the family roles, tasks, and boundaries, on the family structure and function in children with hematological tumors.

METHODSForty children with hematological tumors were randomly divided into SFT and control groups (n=20 each). The control group received conventional chemotherapy. The SFT group received SFT by a trained therapist in addition to conventional chemotherapy; the family of each patient received SFT four times (once every two weeks). Both groups were assessed by the Family Assessment Device (FAD) and Family Environment Scale-Chinese Version (FES-CV) on admission and one month after the end of SFT.

RESULTSAfter treatment, the SFT group showed significant decreases in all factor scores of FAD (P<0.05); the SFT group had significantly lower scores of problem solving, communication, roles, affective involvement, behavior control, and general functioning than the control group (P<0.05). In addition, the SFT group had significantly increased FES-CV scores of cohesion, emotional expression, intellectual-cultural orientation, and active-recreational orientation and a significantly decreased score of conflict after treatment (P<0.05), and the SFT group was significantly superior to the control group in terms of these items (P<0.05).

CONCLUSIONSSFT could promote beneficial family changes in children with hematological tumors by improving the family function and internal environment, which would increase the long-term chemotherapy compliance of these children and their parents.

Humans ; Antibodies, Bispecific/therapeutic use* ; Hematologic Neoplasms/therapy* ; Immunotherapy ; Neoplasms

Fertility ; Hematologic Diseases/therapy* ; Hematologic Neoplasms/therapy* ; Hematopoietic Stem Cell Transplantation ; Humans

Iron is one of the necessary elements for cell growth, proliferation and functional activities. Iron uptake of the vast majority cells, including tumor cells, is primarily mediated by transferrin receptor (TfR). Studies showed that transferrin receptor expressed on tumor cell surface at a high level, thus can be used in the treatment for malignant tumor combined with many kinds of materials. In this article, recent progress of study on transferrin receptor used in treating hematological malignant tumor are reviewed from aspects of transferrin receptor combined with drugs including artemisinin, doxorubicin, gambogic acid and so on, genes, antibodies, polyethylene glycol and nanoparticles.
Hematologic Neoplasms ; metabolism ; therapy ; Humans ; Receptors, Transferrin ; metabolism ; therapeutic use

MicroRNA (miRNA) are small non-coding RNA that act at the post-transcriptional level, regulating protein expression by repressing translation mRNA target. They can be detected in plants, animal species and viruses, and are involved in numerous cellular processes. MicroRNA-155 (miR-155) which is a kind of microRNAs expressed in hematopoietic cells. Recent data indicate that MiR-155 plays a key role in the pathogenesis of hematological malignancies through regulating cell signal transduction pathways of cell proliferation, differentiation and apoptosis, acting predominantly as an oncomir. MiR-155 may be an important indicator to assess the diagnosis, treatment and prognosis of patients with hematological malignancies, including malignant lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It could be suggested that drugs such as antisense oligonucleotides able to down-regulate miR-155 expression would provide a novel, and possibly specific way to control the growth of a range of haematopoietic malignancies in conjunction with classical cytotoxic therapy. The purpose of this review is to summarize current findings on the role of miR-155 in hematopoietic malignancies and, moreover, to highlight their role as potential therapeutic tools.
Animals ; Hematologic Neoplasms ; genetics ; pathology ; therapy ; Humans ; MicroRNAs

Dendritic Cells ; pathology ; Hematologic Neoplasms ; diagnosis ; therapy ; Humans

Bufanolides ; therapeutic use ; Hematologic Neoplasms ; drug therapy ; Humans ; Recurrence